Bimekizumab 3-Year Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Long-Term Pooled Analysis from Five Phase 3 3b Trials. J of Skin 2024, 8 (1), s305. https://doi.org/10.25251/skin.8.supp.305.